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Continuing Education Disclaimer
CDC, our planners, presenters, and their spouses/partners wish to 
disclose they have no financial interests or other relationships with 
the manufacturers of commercial products, suppliers of commercial 
services, or commercial supporters, with the exception of Dr. Mark 
Sullivan and Dr. Joseph Merrill. They would like to disclose that their 
employer, the University of Washington, received a contract payment 
from the Centers for Disease Control and Prevention. 
Planners have reviewed content to ensure there is no bias. 
This presentation will include discussion of the unlabeled use of a 
product or products under investigational use.
Objectives
At the conclusion of this session, the participant will 
be able to:
 Describe the latest guidance for travelers visiting areas with active 
Zika transmission, and differentiate between countries with epidemic 
and endemic Zika.
 Advise patients who are considering or planning to travel on the 
possible Zika risk associated with their travel, and the protective 
measures they can take before, during, and after their trip.
 Apply CDC Zika Laboratory testing algorithms when determining 
which patients with relevant travel history, possible Zika virus 
exposure, or Zika symptoms should receive testing.
 State recommendations for travelers returning from areas with active 
Zika transmission to prevent further transmission of Zika.
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• Review pre-travel counseling recommendations for men and women of 
reproductive age, pregnant women, and women considering pregnancy 
who are planning travel to areas with active Zika virus transmission
• Discuss recommended protective measures for women who live in or 
travel to areas with active Zika virus transmission
• Describe the current guidance regarding the care of pregnant women 
who have possible Zika virus exposure
A Unique Challenge
“…the last time an infectious pathogen (rubella virus) 
caused an epidemic of congenital defects was more than 
50 years ago…”
– New England Journal of Medicine, April 13, 2016
2016 CDC Zika Virus Response
Transitioned to Level 1 Response on 
February 8, 2016
2016 CDC Zika Virus Response
Transitioned to Level 1 Response on 
February 8, 2016
Prior to the Zika virus response, the only Level 1 
activations in CDC history were for Hurricane 
Katrina, H1N1 (Pandemic Flu), and Ebola. 
Active Zika Virus Transmission
61 countries and 
territories 
worldwide, including 
50 countries and 
territories in the 
Americas, reporting 
active Zika virus 
transmission
As of November 21, 2016http://www.cdc.gov/zika/geo/active-countries.html
Zika Virus Infection in Pregnant Women
• Pregnant women can be infected
» Through a mosquito bite 
» Through sex with an infected partner
• If infected during pregnancy
» Zika virus can be passed to the fetus during pregnancy 
or around the time of birth
• If infected around conception
» Zika virus might present a risk to the fetus
Zika Virus is a Cause of Congenital Anomalies
Congenital Zika Syndrome
• A recently described pattern of congenital anomalies associated with Zika 
virus infection during pregnancy
» Severe microcephaly with partially collapsed skull
» Thin cerebral cortices with subcortical calcifications
» Macular scarring and focal pigmentary retinal mottling
» Congenital contractures
» Early hypertonia with symptoms of extrapyramidal involvement
• Congenital Zika virus infection also linked to
» Hearing impairment
» Other neurologic sequelae
Moore CA, Staples D, Dobyns WB, et al. Characterizing the Pattern of Anomalies in Congenital Zika Syndrome . . . JAMA Peds. 3 Nov 2016. 
Congenital Zika Infection without Microcephaly at Birth
• The full spectrum of adverse outcomes caused by Zika virus infection during 
pregnancy remains unknown
• Congenital infection can result in head growth deceleration leading to 
postnatal microcephaly
Linden V, Pessoa A, Dobyns WB, et al. Description of 13 Infants Born During October 2015–January 2016 . . . MMWR. 22 Nov 2016. 
CDC Recommendations: Prevention 
Avoid Traveling to Areas with Active Zika Transmission
• Pregnant women should not travel to 
areas with Zika
• If a pregnant woman must travel, she 
should
» Strictly follow steps to prevent mosquito bites 
» Take steps to prevent sexual transmission




If a pregnant woman travels to an area with Zika, she should
• Wear long-sleeved shirts and long pants
• Stay and sleep in places with air conditioning or that 
use window and door screens
• Use EPA-registered insect repellents with one of the 
following active ingredients 
» DEET, picaridin, IR3535, oil of lemon eucalyptus or para-
menthane-diol, or 2-undecanone
https://www.cdc.gov/zika/prevention/prevent-mosquito-bites.html
Prevent Sexual Transmission of Zika Virus
For couples with a partner who lives in or has recently  
traveled to an area with Zika
• Couples in which a woman is pregnant should
» Use condoms consistently and correctly every time 
they have sex, or abstain from sex
» Not share sex toys
» Follow these precautions for the duration of the 
pregnancy even if the pregnant woman’s partner 
does not have symptoms or feel sick
https://www.cdc.gov/zika/hc-providers/clinical-guidance/sexualtransmission.html
Women and Their Partners Thinking about Pregnancy
• Before a woman or her partner plan travel, they 
should talk to their healthcare provider about their 
plans to become pregnant and the risk of Zika virus 
infection 
• If a woman and/or her partner travel to an area with 
active Zika transmission, they should
» Strictly follow steps to prevent mosquito bites during the 
trip
» Be aware of preconception guidance related to Zika 
virus exposure
https://www.cdc.gov/zika/hc-providers/women-reproductive-age.html





• Preventing unintended pregnancy among people who may be exposed to 
Zika virus is a primary strategy to reduce the number of pregnancies 
affected by Zika virus infection. 
• The best way to reduce risk of unintended pregnancy is to use an effective 
form of birth control consistently and correctly.
https://www.cdc.gov/zika/pregnancy/preventing-pregnancy.html
http://www.cdc.gov/reproductivehealth/contraception/unintendedpregnancy/pdf/contraceptive_methods_508.pdf
CDC Guidance: Pregnancy 
Zika Virus Assessment During Pregnancy
• All pregnant women should be assessed for 
possible Zika virus exposure and signs or 
symptoms of infection at each prenatal care 
visit. 
• They should be asked if they
» Traveled to or live in an area with active Zika virus 
transmission during pregnancy or periconceptional 
period 
» Had sex without a condom with a partner who has 
traveled to or lives in an area with active Zika virus 
transmission
Most common symptoms:




Who should be tested?
• Anyone who has or recently had symptoms 
of Zika virus infection 
» And lives in or recently traveled to an area with 
Zika virus transmission, or
» Had sex without a condom with a partner who 
lived in or traveled to an area with active Zika 
virus transmission
• All pregnant women who 
» Live in or recently traveled to an area with active 
Zika virus transmission, or 
» Had sex without a condom with a partner who 
lives in or recently traveled to an area with 
active Zika virus transmission
http://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6529e1.pdf
Diagnostic Testing for Zika Virus 
Molecular testing
• Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) for 
viral RNA in body fluids or tissues
Serologic testing
• Zika virus immunoglobulin M (IgM) enzyme-linked immunosorbent assay
• Plaque reduction neutralization test (PRNT)
https://www.cdc.gov/zika/laboratories/types-of-tests.html
Diagnostic Testing for Zika Virus 
PRNTs
• PRNTs evaluate neutralizing antibodies in the serum. 
• Neutralizing antibodies develop shortly after IgM and consist primarily of IgG 
antibodies
• Zika virus is a flavivirus, closely related dengue, yellow fever, Japanese 
encephalitis, and West Nile viruses
• After infection with a flavivirus, neutralizing antibodies are expected to 
persist for many years
Rabe IB, Staples JE, Villanueva J, et al. Interim Guidance for Interpretation of Zika Virus Antibody Test Results. MMWR. 3 June 2016.
Limitations of Zika Virus Tests
• Presence of Zika virus RNA is relatively short-lived; negative results do not 
exclude infection
• Testing for Zika virus IgM can produce false positive results because of 
cross-reacting antibodies against related flaviviruses or nonspecific reactivity 
• PRNT levels may not distinguish infecting virus in people previously infected 
with or vaccinated against a related flavivirus
Rabe IB, Staples JE, Villanueva J, et al. Interim Guidance for Interpretation of Zika Virus Antibody Test Results. MMWR. 3 June 2016.
https://www.cdc.gov/zika/pdfs/testing_algorithm.pdf
Evaluation <2 Weeks after Symptoms or Exposure
https://www.cdc.gov/zika/pdfs/testing_algorithm.pdf




Pregnancy & Zika Testing: Interactive Web Algorithm
http://www.cdc.gov/zika/hc-providers/index.html
What CDC is Doing
Many Questions Remain about Zika Virus and its Impact on 
Pregnancies 
• What is the level of risk from Zika virus infection during 
pregnancy?
• When during pregnancy does Zika virus infection pose 
the highest risk to the fetus?
• What is the full range of potential health problems that 
Zika virus infection may cause?
• What are other factors (e.g., co-occurring infection) that 
might affect the risk for birth defects? 
Sample of Current CDC Efforts Related to 
Pregnant Women, Fetuses, & Infants 
US Zika Pregnancy 
Registry







de Embarazadas con 
Zika (Colombia)
Tools for Healthcare Providers and Information for Patients
www.cdc.gov/Zika
*Free materials available in English, Spanish and other languages
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Thank you!
• More information on Zika: 
www.cdc.gov/zika
https://www.cdc.gov/mmwr/zika_reports.html
• Questions about CDC’s work related to Zika: 
contact CDC-INFO at 
800-232-4636 or www.cdc.gov/cdc-info   
Zika Virus Transmission 
and Prevention
Allison Taylor Walker, PhD, MPH
Travelers’ Health Branch
Division of Global Migration and Quarantine
National Center of Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
December 8, 2016
ZIKV
 Single stranded RNA virus
 Genus Flavivirus, family Flaviviridae
 Closely related to dengue, yellow fever, Japanese 
encephalitis (JEV), and West Nile virus (WNV)
Transmission electron microscope image of negative-
stained, Fortaleza-strain ZIKV (red), isolated 
from a microcephaly case in Brazil. 
Photo Credit: www.niaid.nih.gov
Modes of Transmission
 Bite from an infected Aedes species mosquito 




 Sexual transmission from ANY infected partner
 Laboratory exposure
 Probable: blood transfusion
Characteristic
Time of Blood Meal Bite during the day and night
Number of Blood Meals Multiple (Ae. aegypti), single (Ae. albopictus)
Preferred Host(s) Humans (Ae. aegypti), humans and other mammals 
(Ae. albopictus)
Preferred Site to Lay Eggs Containers of standing water (i.e., tires, flower pots)
Vector-borne Diseases Dengue, yellow fever, chikungunya, ZIKV
Environment Urban (Ae. aegypti), urban and rural (Ae. albopictus)
Vector Characteristics
Zika Virus Infection Prevention
Incubation Period, Viremia, and Transmissibility
 Incubation period: 3–14 days
 Viremia: few days–1 week
 Virus can be shed in semen and urine after viremia has resolved
• Viral RNA has been detected in semen as long as 188 days after illness onset
• Duration of transmissibility not established
• To date, cases of sexual transmission have involved exposure within a few weeks of 
illness onset
Musso D, Roche C, et al. Potential sexual transmission of Zika virus. Emerg Infect Dis. 2015;21(2):359-361.
Mansuy JM, et al. Zika virus in semen of a patient returning from a non-epidemic area. Lancet Infect Dis. 2016;16(8):894-895. 
Recommendations for Prevention of Sexual Transmission
 Couples in which a woman is pregnant 
• Use condoms or abstain from sex throughout pregnancy
 Couples who are not pregnant and one or both partners 
have traveled to or live in an area with ZIKV
• Use condoms (male or female) or abstain from sex (vaginal, 
anal, oral, and sharing of sex toys) as follows:
o Men: At least 6 months after symptom onset or last 
possible exposure (if asymptomatic)
o Women: At least 8 weeks after symptom onset or last 
possible exposure (if asymptomatic) 
Petersen EE, et al. Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Persons 
with Possible Zika Virus Exposure — United States, September 2016. MMWR. ePub: 30 September 2016. 
Mosquito Bite Protection
 Wear long-sleeved shirts and long pants
 Stay and sleep in places with air conditioning, when possible, and use window 
and door screens to keep mosquitoes outside
 Take steps to control mosquitoes indoors and outdoors
 Personal protection:
• Use EPA-registered insect repellents with either DEET, picaridin, IR3535, para-menthane-
diol (PMD), oil of lemon eucalyptus (OLE), 2-undecanone and follow label directions
o PMD and OLE should not be used in children <3 years
• Apply sunscreen before insect repellent
http://www.nc.cdc.gov/travel/page/avoidbug-bites
What People Infected with ZIKV or Possibly 
Exposed to ZIKV Can Do to 
Protect Others
 Protect from mosquito bites for 3 weeks after leaving an 
area with Zika
• 3 weeks = Incubation weeks + viremic week
• When viremic, ZIKV can be passed to a mosquito and to other people
Zika Virus Disease Risk in Countries with Active 
and Previous Zika Virus Transmission
Risk to Travelers
 Countries with active Zika virus transmission 
• Travel notices
• Immunologically naïve population
• Competent vector
 Countries with previously documented Zika virus transmission
• CDC does not issue travel notices in non-outbreak settings
• Population immunity at an unknown level
• Likely lower vector burden
• Likely lower force of infection







Level 1, Watch Follow usual precautions Measles, Chikungunya
Level 2, Alert Use enhanced precautions Zika, Rubella
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Level 1, Watch Follow usual precautions Measles, Chikungunya
Level 2, Alert Use enhanced precautions Zika, Rubella
Level 3, Warning Avoid nonessential travel Ebola, Haiti Earthquake
Watch Alert Warning
Travel Notices
Countries and Territories with Active ZIKV Transmission: AMERICAS 
(current as of December 5, 2016)
 Anguilla

















































 Saint Kitts and 
Nevis
 Suriname
 Trinidad and 
Tobago
 Turks and Caicos
 United States
 U.S. Virgin Islands
 Venezuela
Countries and Territories with Active ZIKV Transmission: Outside the Americas




























































 CDC maintains a 24/7 consultation service for health officials and 
healthcare providers caring for pregnant women with Zika virus infection 
(suspect or confirmed)
• To contact the service:
o Call: 770-488-7100
o Email: ZIKAMCH@cdc.gov







 Text messaging service
• Text “PLAN” to 855-255-5606 to subscribe
 TravWell mobile application
• Destination-specific vaccine recommendations
• Packing and to do lists
• Notifications from CDC about disease outbreaks
To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Thank you for joining!
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Today’s webinar  will be archived
When:  A few days after the live call
What:  All call recordings (audio, webinar, and 
transcript)




registration is not required
Effectively Communicating with Patients 
about Opioid Therapy
 Date: Tuesday, December 13, 2016
 Time: 2:00 – 3:00 pm (Eastern)
 Presenters:
 Deborah Dowell, MD, MPH—CDC
 David J. Tauben, MD, FACP—University of Washington
 Joseph O. Merrill MD, MPH—University of Washington
http://emergency.cdc.gov/coca
Continuing Education  for COCA Calls
All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and 
AAVSB/RACE) for COCA Calls are issued online through the CDC Training 
& Continuing Education Online system (http://www.cdc.gov/TCEOnline/).
Those who participated in today’s COCA Call and who wish to receive 
continuing education  should complete the online evaluation by January 
9, 2017 with the course code WC2286. Those who will participate in the on 
demand activity and wish to receive continuing education should 
complete the online evaluation between January 9, 2017 and December 7, 
2018 will use course code WD2286. 
Continuing education certificates can be printed immediately upon 
completion of your online evaluation. A cumulative transcript of all 
CDC/ATSDR CE’s obtained through the CDC Training & Continuing 
Education Online System will be maintained for each user. 
Join the COCA Mailing 
List
Receive information about:
• Upcoming COCA Calls
• Health Alert Network notices
• CDC public health activations
• Emerging health threats
• Emergency preparedness and 
response conferences and 
training opportunities
http://emergency.cdc.gov/coca 
Join Us on 
Facebook
CDC Facebook page 
for clinicians! “Like” 
our page today to 
learn about upcoming 




CDC Clinician Outreach and Communication Activity
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity
